Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease

So-Ryoung Lee; Jin‐Hyung Jung; Eue-Keun Choi; Seung‐Woo Lee; Soonil Kwon; Ji-Suck Park; Jeehoon Kang; Kyungdo Han; Kyung Woo Park; Seil Oh; Professor Gregory Lip

doi:10.3389/fcvm.2022.991293

Abstract

1 min read

Oral anticoagulant monotherapy may be a comparable choice for patients with AF and stable CAD compared to OAC plus SAPT. In patients with stable CAD more than 3-year after index PCI, OAC monotherapy would be a better choice, being associated with less major bleeding and a positive net clinical benefit.

Related publications

Article2018

Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation　― The Fushimi AF Registry ―

Nobutoyo Masunaga, Mitsuru Abe, Hisashi Ogawa, Yuya Aono, Syuhei Ikeda, Kosuke Doi, Yoshimori An, Mitsuru Ishii, Moritake Iguchi, Masahiro Esato, Hikari Tsuji, Hiromichi Wada, Koji Hasegawa, Professor Gregory Lip, Masaharu Akao

Article2023

Oral anticoagulation among frail patients with atrial fibrillation: assessment of net clinical benefit in a nationwide cohort

Peter Brønnum Nielsen, Martin Jensen, A A Hoejen, Torben Bjerregaard Larsen, Professor Gregory Lip, Anne Gulbech Ording, M Soegaard

Article2020

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention

M Mihajlović, M Marinković, Monika Kozieł, Nebojša Mujović, Professor Gregory Lip, Tatjana Potpara

Article2020

Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention

Jiesuck Park, Eue-Keun Choi, Kyungdo Han, Bongseong Kim, You‐Jung Choi, So-Ryoung Lee, Jeehoon Kang, Myung‐Jin Cha, Kyung Woo Park, Seil Oh, Professor Gregory Lip

Article2020

Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting

Monika Kozieł, Tatjana Potpara, Professor Gregory Lip

Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease

Abstract

Discussion(0)

Related publications

Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation ― The Fushimi AF Registry ―

Oral anticoagulation among frail patients with atrial fibrillation: assessment of net clinical benefit in a nationwide cohort

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention

Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention

Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting

Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation　― The Fushimi AF Registry ―